BrainCool AB (publ)

OM:BRAIN Stock Report

Market Cap: SEK 408.0m

BrainCool Valuation

Is BRAIN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BRAIN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BRAIN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BRAIN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BRAIN?

Key metric: As BRAIN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BRAIN. This is calculated by dividing BRAIN's market cap by their current revenue.
What is BRAIN's PS Ratio?
PS Ratio9.8x
SalesSEK 40.67m
Market CapSEK 407.96m

Price to Sales Ratio vs Peers

How does BRAIN's PS Ratio compare to its peers?

The above table shows the PS ratio for BRAIN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16.1x
ACARIX Acarix
58.8x109.8%SEK 334.0m
INTEG B Integrum
4x29.7%SEK 440.3m
BOUL Boule Diagnostics
0.5x6.4%SEK 286.6m
CARE Careium
0.8x10.2%SEK 705.5m
BRAIN BrainCool
9.8xn/aSEK 399.9m

Price-To-Sales vs Peers: BRAIN is good value based on its Price-To-Sales Ratio (9.8x) compared to the peer average (16.1x).

Price to Sales Ratio vs Industry

How does BRAIN's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

12 CompaniesPrice / SalesEstimated GrowthMarket Cap
ARJO B Arjo
0.8x3.7%US$816.55m
CARE Careium
0.8x10.2%US$63.74m
BOUL Boule Diagnostics
0.5x6.4%US$25.89m
ARCOMA Arcoma
0.9x8.3%US$13.22m
BRAIN 9.8xIndustry Avg. 4.7xNo. of Companies12PS048121620+
12 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BRAIN is expensive based on its Price-To-Sales Ratio (9.8x) compared to the Swedish Medical Equipment industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is BRAIN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BRAIN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BRAIN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Arcoma

SEK 146.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 11.10

7D

2.8%

1Y

49.0%

Mentice

SEK 560.0m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 21.90

7D

2.8%

1Y

-46.6%

Dignitana

SEK 95.8m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.19

7D

3.5%

1Y

-45.9%